Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial

被引：0
|
作者：
Hu, Chao-su
Xue, Fen
Ou, Dan
Xie, Congying
Lin, Shaojun
Li, Jingao
Chen, Xiaozhong
Zhang, Fuzheng
Ying, Hongmei
Lu, Xueguan
Shen, Chunying
Xu, Tingting
Ou, Xiaomin
Zhou, Xin
Du, Chengrun
Li, Weiwei
He, Xiayun
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China
[3] Fujian Prov Canc Hosp, Fuzhou, Fujian, Peoples R China
[4] Jiangxi Canc Hosp, Dept Radiat Oncol, Nanchang, Jiangxi, Peoples R China
[5] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[6] Jiangnan Univ, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China
[7] Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6075
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
    Chen, Qiuyan
    Tang, Linquan
    Liu, Na
    Han, Feng
    Guo, Ling
    Guo, Shanshan
    Wang, Jianwei
    Liu, Huai
    Ye, Yanfang
    Zhang, Lu
    Liu, Liting
    Wang, Pan
    Li, Yingqin
    He, Qingmei
    Yang, Xiaoqun
    Tang, Qingnan
    Li, Yang
    Liang, YuJing
    Sun, XueSong
    Xie, Chuanmiao
    Mo, Yunxian
    Guo, Ying
    Sun, Rui
    Mo, Haoyuan
    Cao, Kajia
    Guo, Xiang
    Zeng, Musheng
    Mai, Haiqiang
    Ma, Jun
    CANCER COMMUNICATIONS, 2018, 38
  • [42] Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study
    Zhang, Bin
    Hu, Ying
    Xiong, Rui-Hua
    Pan, Yu-Fei
    Xu, Qian-Lan
    Kong, Xiang-Yun
    Cai, Rui
    Chen, Qiu-Qiu
    Tang, Hua-Ying
    Jiang, Wei
    ONCOTARGET, 2017, 8 (08) : 14078 - 14088
  • [43] Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
    Liu, Li-Ting
    Liu, Huai
    Huang, Ying
    Yang, Jin-Hao
    Xie, Si-Yi
    Li, Yuan-Yuan
    Guo, Shan-Shan
    Qi, Bin
    Li, Xiao-Yun
    Chen, Dong-Ping
    Jin, Feng
    Sun, Xue-Song
    Yang, Zhen-Chong
    Liu, Sai-Lan
    Luo, Dong-Hua
    Li, Ji-Bin
    Liu, Qing
    Wang, Pan
    Guo, Ling
    Mo, Hao-Yuan
    Qiu, Fang
    Yang, Qi
    Liang, Yu-Jing
    Jia, Guo-Dong
    Wen, Dong-Xiang
    Yan, Jin-Jie
    Zhao, Chong
    Chen, Qiu-Yan
    Sun, Rui
    Tang, Lin-Quan
    Mai, Hai-Qiang
    LANCET ONCOLOGY, 2023, 24 (07): : 798 - 810
  • [44] Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma
    Wang, Qiaoli
    Xu, Guoqiang
    Xia, Yaoxiong
    Zuo, Jia
    Zeng, Guilin
    Xue, Zhihong
    Cao, Ruixue
    Xiong, Wei
    Li, Wenhui
    ORAL ONCOLOGY, 2020, 111
  • [45] Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A prospective, single-arm, phase II trial
    Li, M.
    Qu, S.
    Lan, G.
    Shi, M.
    Wang, Y.
    Ban, M.
    Weng, J.
    Wei, J.
    Huang, W.
    Gui, Z.
    Mao, X.
    Huang, X.
    Xie, S.
    Wang, H.
    Huang, B.
    Qin, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S632 - S632
  • [46] Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979).
    Liang, Hu
    Xia, Wei-Xiong
    Lv, Xing
    Sun, Rui
    Zeng, Qi
    Li, Si -Wei
    Mo, Hao-Yuan
    Han, Fei
    Luo, Dong-Hua
    Ye, Yan-Fang
    Yang, Jing
    Ke, Liang-Ru
    Guo, Ling
    Chen, Ming-Yuan
    Cao, Ka-Jia
    Zhao, Chong
    Mai, Hai-Qiang
    Qian, Chao-Nan
    Guo, Xiang
    Yanqun, Xiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2-3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trial
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    Guo, Shan-Shan
    Li, Xiao-Yun
    Liu, Li-Ting
    Jia, Guo-Dong
    Liu, Sai Lan
    Sun, Xue-Song
    Lv, Xing
    Xiang, Yan-Qun
    Luo, Dong-Hua
    Sun, Rui
    Qi, Yang
    Liu, Qing
    Li, Ji-Bin
    Mo, Hao-Yuan
    Guo, Ling
    Zhao, Chong
    Guo, Xiang
    Tang, Lin-Quan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: A retrospective study
    He, Jiaqi
    Luo, Guoqing
    Liu, Shen
    Chen, Lingli
    Chen, Zihong
    Zhang, Bing
    Lin, Jiong
    Qin, Wenyi
    Li, Haiwen
    Zhou, Haideng
    Yu, Ying
    Zhan, Dechao
    Yang, Donghong
    Luo, Haiqing
    TRANSLATIONAL ONCOLOGY, 2024, 48
  • [49] Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
    Guoqiang, X.
    Wei, X.
    Qiaoli, W.
    Ruixue, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1353 - S1353
  • [50] Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
    Tao, Hao-Yun
    Zhan, Ze-Jiang
    Qiu, Wen-Ze
    Liao, Kai
    Yuan, Ya-Wei
    Yuan, Tai-Ze
    Zheng, Rong-Hui
    JOURNAL OF CANCER, 2021, 12 (01): : 18 - 27
12345